91女神

Skip to main content

COVID-19 Vaccine Trials to be Conducted at 91女神, Washington University

07/21/2020Media Inquiries

Carrie Bebermeyer
Public Relations Director
carrie.bebermeyer@slu.edu
314-977-8015

Reserved for members of the media.

07/21/2020

Vaccine Trials to Enroll About 3,000 Area Residents

ST. LOUIS 鈥� As U.S. scientists ramp up a national effort to evaluate COVID-19 vaccine candidates at clinical trial sites across the country, researchers at the Saint Louis University Center for Vaccine Development and Washington University School of Medicine in St. Louis have been tapped to join the historic effort to find a COVID-19 vaccine that can prevent the illness.

Researchers at the two universities expect to enroll about 3,000 participants in several COVID-19 vaccine trials, with each school participating in different trials.

Researchers say it will be critically important to enroll participants who are likely to be exposed to COVID-19 or those at risk for severe disease from COVID-19, including participants over age 65.

Doisy Research Center

Part of the 91女神 School of Medicine, 91女神's Center for Vaccine Development is located in the Edward A. Doisy Research Center, pictured above. File photo

COVID-19 Prevention Network

91女神 and Washington University School of Medicine in St. Louis are participating in the trials as a part of the (CoVPN), a newly organized network formed by the National Institute of Allergy and Infectious Diseases (NIAID) to develop and test vaccines and treatments in the fight against COVID-19.

The COVID-19 Prevention Network will participate in large-scale phase 3 vaccine trials that will enroll thousands of participants from across the U.S. or in some cases around the world to determine whether the vaccines can prevent COVID-19 disease.

The COVID-19 Prevention Network brings together several existing NIH networks, including:

Each of the networks has expertise in conducting clinical trials and is quickly pivoting to evaluate potential COVID-19 vaccines.

Leaders in the Field

Locally, 91女神 and Washington University are well positioned to conduct the COVID-19 vaccine trials, with extensive expertise in infectious disease research.

The 91女神 Center for Vaccine Development is home to one of 10 Vaccine and Treatment Evaluation Units in the United States. As such, 91女神 conducts Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners.

鈥淭he Center for Vaccine Development at 91女神 has 30 years of experience testing novel vaccines and completing urgent pandemic vaccine trials,鈥� said Daniel Hoft, MD, PhD, director of the 91女神 Center for Vaccine Development and principal investigator for the VTEU. 鈥淲e recognize that particularly in these unprecedented times, collaboration is critically important. We look forward to using the collective strengths at 91女神 and Washington University to get COVID-19 vaccines ready for the U.S. public and world.鈥�

Washington University School of Medicine has more than 30 years鈥� experience leading clinical trials evaluating new treatments and vaccines for infectious diseases through its Infectious Disease Clinical Research Unit and the AIDS Clinical Trials Group. The latter has been instrumental in conducting trials to control the HIV pandemic, leading to safe and effective medications that treat and prevent HIV infection and AIDS.

鈥淥ur long history of working with the HIV community has demonstrated how critically important community support is in conducting successful clinical trials,鈥� said Rachel Presti, MD, PhD, an associate professor of medicine, director of Washington University鈥檚 Infectious Disease Clinical Research Unit and principal investigator for the AIDS Clinical Trials Group and the HIV Prevention Trials Network. 鈥淲e are excited that the St. Louis community will have this opportunity to participate in historic clinical trials aimed at helping to identify the most effective vaccines for preventing COVID-19.鈥�

Partnering with the Community

鈥淪t. Louisans will be key to the success of the vaccine trials,鈥� said Sharon Frey, MD, clinical director of 91女神鈥檚 Center for Vaccine Development and principal investigator of the trial at 91女神. 鈥淎 powerful example of the role the St. Louis community plays in advancing public health was seen in the community鈥檚 response to the 2009 pandemic influenza vaccine trial. We are deeply grateful for the support of the St. Louis community as we launch these trials, which represent our best hope to fight back against the COVID-19 pandemic.鈥�

鈥淭his is where we begin to really fight back against the scourge of COVID-19,鈥� said Washington University lead research coordinator Michael Klebert, PhD, an instructor of medicine. 鈥淭he collaboration of two world-class medical schools with the support of volunteers from the St. Louis community in this effort will be a powerful combination. We are looking forward to the challenge.鈥�

91女神 and Washington University will share additional information about the trials as it becomes available.

For more information about vaccines trials at Washington University School of Medicine, please email idcru@wustl.edu or call 314-454-0058.

For more information about vaccine trials at 91女神鈥檚 Center for Vaccine Development, please visit vaccine.slu.edu; call 314-977-6333 or 1-866-410-6333; or email vaccine@slu.edu.

The Washington University HIV Clinical Trials Unit is supported by the National Institutes of Health (NIH), grant numbers 5UM1AI069439-15 and 3UM1AI069439-15S1.

The 91女神 project is funded under cooperative agreement number UM1 AI148685.

About the Washington University School of Medicine 
鈥檚 1,500 faculty physicians also are the medical staff of and hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children鈥檚 hospitals, the School of Medicine is linked to .

About the 91女神 School of Medicine 
Established in 1836, 91女神 School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: infectious disease, liver disease, cancer, heart/lung disease, and aging and brain disorders.